Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
68.55(c) 68.61(c) 68.6(c) 69.64(c) 71(c) Last
350 434 158 893 135 649 170 859 237 557 Volume
+2.80% +0.09% -0.01% +1.52% +1.95% Change
More quotes
Financials (€)
Sales 2017 55,3 M
EBIT 2017 -52,2 M
Net income 2017 -67,0 M
Finance 2017 267 M
Yield 2017 -
Sales 2018 49,3 M
EBIT 2018 -56,2 M
Net income 2018 -67,1 M
Finance 2018 221 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 32,8x
EV / Sales2018 37,7x
Capitalization 2 083 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery and Proprietary Development.The Partnered Discovery segment involves technologies for the generation of human antibody... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
09/22 MORPHOSYS : Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studie..
09/21 MORPHOSYS : Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studie..
09/21 MORPHOSYS : Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studie..
09/19 MORPHOSYS : Announces that its Licensee Janssen received CHMP Positive Opinion f..
09/18 MORPHOSYS : Announces that its Licensee Janssen received CHMP Positive Opinion f..
09/18 MORPHOSYS : Announces that its Licensee Janssen received CHMP Positive Opinion f..
09/05 MORPHOSYS : Presents Vision for Growth at its Capital Markets Day
09/05 MORPHOSYS : Presents Vision for Growth at its Capital Markets Day
08/10 MORPHOSYS AG : MorphoSys to Present at Upcoming Investor Conferences
08/10 DGAP-NEWS : MorphoSys to Present at Upcoming Investor Conferences
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/21MorphoSys AG given €76.00 PT by Commerzbank Ag. buy rating.  
09/21MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studi.. 
09/19MorphoSys AG given €68.00 PT by Berenberg Bank. buy rating.  
09/19MorphoSys AG given €55.00 PT by Goldman Sachs Group, Inc. (The). neutral rati.. 
09/18MorphoSys Long: 150-Prozent-Chance | InvestorSMS  
More tweets
Qtime:15
News from SeekingAlpha
09/22 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 22, 2017
09/19 Morphosys AG (MPSYY) Presents At Berenberg & Goldman Sachs Sixth German Corpo..
09/06 Morphosys (MPSYY) Investor Presentation - Slideshow
08/05 MorphoSys AG 2017 Q2 - Results - Earnings Call Slides
08/05 Morphosys' (MPSYF) CEO Simon Moroney on Q2 2017 Results - Earnings Call Trans..
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 72,8 €
Spread / Average Target 2,5%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Günter Wellnhofer Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG45.64%2 489
INCYTE CORPORATION14.74%23 351
QUINTILES IMS HOLDINGS INC23.89%20 370
LONZA GROUP56.52%19 634
CELLTRION, INC.--.--%15 568
ALNYLAM PHARMACEUTICALS, INC.201.60%10 439